Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
13681 | 820 | 48.2 | 92% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
449 | 3 | FAMILIAL MEDITERRANEAN FEVER//TOLL LIKE RECEPTORS//INFLAMMASOME | 25887 |
543 | 2 | TOLL LIKE RECEPTORS//INNATE IMMUNITY//CPG ODN | 14712 |
13681 | 1 | TOLL LIKE RECEPTORS//TOLL LIKE RECEPTOR 9//TLR4 | 820 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | TOLL LIKE RECEPTORS | authKW | 211580 | 21% | 3% | 173 |
2 | TOLL LIKE RECEPTOR 9 | authKW | 148895 | 4% | 13% | 30 |
3 | TLR4 | authKW | 129722 | 8% | 5% | 68 |
4 | TOLL LIKE RECEPTOR 4 | authKW | 101440 | 7% | 5% | 60 |
5 | TOLL LIKE RECEPTOR 3 | authKW | 85077 | 2% | 11% | 20 |
6 | 95D CELL | authKW | 74474 | 0% | 100% | 2 |
7 | DSRNA THERAPY | authKW | 74474 | 0% | 100% | 2 |
8 | TLR9 | authKW | 59700 | 3% | 7% | 24 |
9 | LIVER SMMU | address | 49648 | 0% | 67% | 2 |
10 | ORAL SQAUMOUS CELL CARCINOMA | authKW | 49648 | 0% | 67% | 2 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 6990 | 48% | 0% | 392 |
2 | Immunology | 1601 | 22% | 0% | 183 |
3 | Cell Biology | 391 | 13% | 0% | 106 |
4 | Gastroenterology & Hepatology | 346 | 7% | 0% | 57 |
5 | Medicine, Research & Experimental | 340 | 9% | 0% | 71 |
6 | Pathology | 132 | 4% | 0% | 35 |
7 | Biochemistry & Molecular Biology | 62 | 12% | 0% | 98 |
8 | Genetics & Heredity | 43 | 5% | 0% | 37 |
9 | Dentistry, Oral Surgery & Medicine | 25 | 2% | 0% | 16 |
10 | Hematology | 22 | 2% | 0% | 20 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | LIVER SMMU | 49648 | 0% | 67% | 2 |
2 | ACUPUNCTURE 5 | 37237 | 0% | 100% | 1 |
3 | AFFILIATE JIANGSU PEOPLES HOSP | 37237 | 0% | 100% | 1 |
4 | AFFILIATED CHANG ZHENG HOSP | 37237 | 0% | 100% | 1 |
5 | AFFILLIATED ZHONGDA HOSP | 37237 | 0% | 100% | 1 |
6 | ANAL DIS | 37237 | 0% | 100% | 1 |
7 | ANAT HISTOL FORENS ORTHOPAED SCI DAHFMO | 37237 | 0% | 100% | 1 |
8 | ANHUI PROV PATHOGEN BIOL ZOONOSES | 37237 | 0% | 100% | 1 |
9 | BREAST VASC SURG | 37237 | 0% | 100% | 1 |
10 | CANC CANC CONTROL LIAONING PROV | 37237 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ONCOIMMUNOLOGY | 5591 | 1% | 1% | 12 |
2 | TUMOR BIOLOGY | 2903 | 3% | 0% | 22 |
3 | CANCER IMMUNOLOGY IMMUNOTHERAPY | 2751 | 2% | 0% | 18 |
4 | INNATE IMMUNITY | 1812 | 1% | 1% | 5 |
5 | CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY | 1549 | 1% | 1% | 5 |
6 | FRONTIERS IN IMMUNOLOGY | 1266 | 1% | 0% | 10 |
7 | BMC CANCER | 985 | 2% | 0% | 14 |
8 | ONCOTARGETS AND THERAPY | 943 | 1% | 0% | 7 |
9 | CANCER BIOLOGY & THERAPY | 836 | 1% | 0% | 8 |
10 | CANCER RESEARCH | 759 | 4% | 0% | 29 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | TOLL LIKE RECEPTORS | 211580 | 21% | 3% | 173 | Search TOLL+LIKE+RECEPTORS | Search TOLL+LIKE+RECEPTORS |
2 | TOLL LIKE RECEPTOR 9 | 148895 | 4% | 13% | 30 | Search TOLL+LIKE+RECEPTOR+9 | Search TOLL+LIKE+RECEPTOR+9 |
3 | TLR4 | 129722 | 8% | 5% | 68 | Search TLR4 | Search TLR4 |
4 | TOLL LIKE RECEPTOR 4 | 101440 | 7% | 5% | 60 | Search TOLL+LIKE+RECEPTOR+4 | Search TOLL+LIKE+RECEPTOR+4 |
5 | TOLL LIKE RECEPTOR 3 | 85077 | 2% | 11% | 20 | Search TOLL+LIKE+RECEPTOR+3 | Search TOLL+LIKE+RECEPTOR+3 |
6 | 95D CELL | 74474 | 0% | 100% | 2 | Search 95D+CELL | Search 95D+CELL |
7 | DSRNA THERAPY | 74474 | 0% | 100% | 2 | Search DSRNA+THERAPY | Search DSRNA+THERAPY |
8 | TLR9 | 59700 | 3% | 7% | 24 | Search TLR9 | Search TLR9 |
9 | ORAL SQAUMOUS CELL CARCINOMA | 49648 | 0% | 67% | 2 | Search ORAL+SQAUMOUS+CELL+CARCINOMA | Search ORAL+SQAUMOUS+CELL+CARCINOMA |
10 | MYD88 | 43211 | 3% | 5% | 25 | Search MYD88 | Search MYD88 |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | DAJON, M , IRIBARREN, K , CREMER, I , (2017) TOLL-LIKE RECEPTOR STIMULATION IN CANCER: A PRO- AND ANTI-TUMOR DOUBLE-EDGED SWORD.IMMUNOBIOLOGY. VOL. 222. ISSUE 1. P. 89 -100 | 73 | 56% | 3 |
2 | YU, L , WANG, LT , CHEN, SW , (2013) DUAL CHARACTER OF TOLL-LIKE RECEPTOR SIGNALING: PRO-TUMORIGENIC EFFECTS AND ANTI-TUMOR FUNCTIONS.BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER. VOL. 1835. ISSUE 2. P. 144 -154 | 71 | 59% | 18 |
3 | BASITH, S , MANAVALAN, B , YOO, TH , KIM, SG , CHOI, S , (2012) ROLES OF TOLL-LIKE RECEPTORS IN CANCER: A DOUBLE-EDGED SWORD FOR DEFENSE AND OFFENSE.ARCHIVES OF PHARMACAL RESEARCH. VOL. 35. ISSUE 8. P. 1297-1316 | 71 | 50% | 58 |
4 | YU, L , WANG, LT , CHEN, SW , (2012) EXOGENOUS OR ENDOGENOUS TOLL-LIKE RECEPTOR LIGANDS: WHICH IS THE MVP IN TUMORIGENESIS?.CELLULAR AND MOLECULAR LIFE SCIENCES. VOL. 69. ISSUE 6. P. 935 -949 | 71 | 53% | 13 |
5 | MAI, CW , KANG, YB , PICHIKA, MR , (2013) SHOULD A TOLL-LIKE RECEPTOR 4 (TLR-4) AGONIST OR ANTAGONIST BE DESIGNED TO TREAT CANCER? TLR-4: ITS EXPRESSION AND EFFECTS IN THE TEN MOST COMMON CANCERS.ONCOTARGETS AND THERAPY. VOL. 6. ISSUE . P. 1573-1587 | 73 | 46% | 26 |
6 | ZOU, H , WANG, WK , LIU, YL , BRADDOCK, M , ZHENG, MH , HUANGG, DS , (2016) TOLL-LIKE RECEPTORS IN HEPATOCELLULAR CARCINOMA: POTENTIAL NOVEL TARGETS FOR PHARMACOLOGICAL INTERVENTION.EXPERT OPINION ON THERAPEUTIC TARGETS. VOL. 20. ISSUE 9. P. 1127 -1135 | 50 | 56% | 0 |
7 | ZHU, LB , YUAN, H , JIANG, T , WANG, RX , MA, HX , ZHANG, SY , (2013) ASSOCIATION OF TLR2 AND TLR4 POLYMORPHISMS WITH RISK OF CANCER: A META-ANALYSIS.PLOS ONE. VOL. 8. ISSUE 12. P. - | 39 | 64% | 9 |
8 | SEMLALI, A , JALOULI, M , PARINE, NR , AL AMRI, A , ARAFAH, M , AL NAEEM, A , AJAJ, SA , ROUABHIA, M , ALANAZI, MS , (2017) TOLL-LIKE RECEPTOR 4 AS A PREDICTOR OF CLINICAL OUTCOMES OF ESTROGEN RECEPTOR-NEGATIVE BREAST CANCER IN SAUDI WOMEN.ONCOTARGETS AND THERAPY. VOL. 10. ISSUE . P. 1207 -1216 | 34 | 65% | 0 |
9 | GOMAZ, A , PAVELIC, J , GLAVAN, TM , (2012) THE POLYMORPHISMS IN TOLL-LIKE RECEPTOR GENES AND CANCER RISK.PERIODICUM BIOLOGORUM. VOL. 114. ISSUE 4. P. 461-469 | 35 | 69% | 0 |
10 | KHAN, AA , KHAN, Z , WARNAKULASURIYA, S , (2016) CANCER-ASSOCIATED TOLL-LIKE RECEPTOR MODULATION AND INSINUATION IN INFECTION SUSCEPTIBILITY: ASSOCIATION OR COINCIDENCE?.ANNALS OF ONCOLOGY. VOL. 27. ISSUE 6. P. 984 -997 | 54 | 36% | 1 |
Classes with closest relation at Level 1 |